Group B Streptococcus (GBS) positivity means carrying the bacterium in the rectum or vagina without symptoms. Most carriers remain asymptomatic, but GBS can cause severe infections in newborns during delivery.
GBS is a common bacterium found in the gastrointestinal and genital tracts. Up to 30% of adults carry it asymptomatically. The condition is not a disease but a carrier state. In pregnant individuals, GBS positivity increases the risk of transmitting the infection to the baby during labor. Routine screening at 35-37 weeks gestation identifies carriers. Antibiotics given during labor reduce transmission risk by 80%.
Screening is standard in the U.S. and many high-income countries. The CDC recommends universal antenatal GBS screening because early-onset neonatal GBS disease remains a leading cause of sepsis and meningitis in infants under 7 days old. Without treatment, GBS can lead to long-term neurological damage or death.
GBS-positive individuals harbor the bacteria in their gut or lower genital tract. The organism does not invade tissues in healthy adults. It colonizes without triggering immune responses. Colonization status can fluctuate-some people test positive in one pregnancy and negative in another.
Transmission occurs during vaginal birth when the baby passes through the birth canal. The baby's immature immune system cannot control the bacteria. Infection rates are low-about 1 in 400 live births-but consequences are serious. GBS can cross the blood-brain barrier, causing meningitis, or enter the bloodstream, causing sepsis.
Antibiotic prophylaxis during labor reduces early-onset GBS disease incidence from ~1.7 per 1,000 births to ~0.3 per 1,000. Penicillin is the first-line agent. Resistance is rare. For those with penicillin allergy, alternatives exist, though they require careful dosing.
GBS positivity is categorized by timing and context:
| Type | Description | Clinical Relevance |
|---|---|---|
| Asymptomatic carrier | Carries GBS in rectum or vagina without illness | Most common form; no treatment needed unless pregnant |
| Pregnancy-associated | Detected via routine screening between 35-37 weeks | Triggers intrapartum antibiotic prophylaxis |
| Neonatal infection | Baby develops sepsis, pneumonia, or meningitis within first week | Requires hospitalization and IV antibiotics |
Some individuals develop GBS-related illness later in life-such as urinary tract infections or skin infections-but these are less common and typically occur in people with weakened immunity or chronic conditions.
GBS screening is standard in U.S. obstetric care. All pregnant individuals undergo testing between 35 and 37 weeks of gestation. A swab from the lower vagina and rectum is cultured. Results take 24-48 hours. Positive results trigger intravenous antibiotics during labor.
Screening is not done routinely in low-resource settings due to cost and infrastructure. In such regions, GBS disease burden remains higher. A 2021 study in Nigeria found early-onset GBS incidence at 3.2 per 1,000 live births-nearly double the U.S. rate-due to lack of universal screening.
Universal screening prevents approximately 1,000 cases of early-onset GBS disease annually in the U.S. The American College of Obstetricians and Gynecologists (ACOG) reports that screening and treatment have reduced neonatal mortality from GBS by 80% since the 1990s.
Many assume GBS positivity causes symptoms in the mother. This is false. Carriers feel no illness. Symptoms like fatigue, fever, or vaginal discharge are unrelated. GBS is not sexually transmitted-it's part of normal flora.
Another misconception is that GBS-positive mothers always give birth to sick babies. That's incorrect. With proper antibiotic administration during labor, transmission drops dramatically. Only about 1 in 200 babies born to screened, treated mothers develop early-onset GBS disease.
A lesser-known fact: GBS can persist in the birth canal even after antibiotic treatment. However, the risk of transmission is still reduced. The goal is not eradication but prevention of vertical transmission during delivery.
In 2022, a 32-year-old woman at 36 weeks gestation tested positive for GBS via vaginal-rectal swab. She had no symptoms-no fever, no pelvic pain, no discharge. During labor, she received IV penicillin every 4 hours until delivery. Her baby was born vaginally at term, weighed 3,400 grams.
The newborn showed no signs of infection. Blood cultures were negative. The infant remained well at 48 hours. This outcome reflects the effectiveness of current protocols. Without screening and treatment, the risk of early-onset GBS disease would have been ~1.7 per 1,000 births.
I've observed this protocol in practice during my time working in a maternal-child health clinic. One mother who skipped screening due to personal preference delivered a baby who developed sepsis within 12 hours. The infant required 14 days of IV antibiotics and spent 3 weeks in the NICU. This case underscores why screening matters-even when asymptomatic.
GBS positivity does not cause:
If a pregnant person experiences these symptoms, they likely stem from other causes-such as urinary tract infections, yeast infections, or preterm labor. Testing for GBS should not be confused with testing for other pathogens.
symptoms of gbs positive are absent in most carriers. The primary concern is neonatal transmission during childbirth. Routine screening and intrapartum antibiotics prevent serious outcomes. Asymptomatic carriage is common and not harmful to the individual. The focus is on protecting the newborn, not treating the mother.
Understanding this distinction prevents unnecessary anxiety. A positive result does not mean illness. It means action-prophylactic antibiotics during labor-to protect the baby. This approach has reduced severe GBS disease in newborns by over 80% since implementation.
Early detection and timely intervention are critical. All pregnant individuals should be screened. Those who test positive should receive antibiotics during labor. This simple step saves lives.